Literature DB >> 34567940

Experience with nasogastric tube administration of tirabrutinib in the treatment of an elderly patient with primary central nervous system lymphoma.

Hiromasa Yoshioka1, Takeshi Okuda1, Takayuki Nakao1, Mitsugu Fujita1,2, Jun C Takahashi1.   

Abstract

We report that tirabrutinib was administered via nasogastric tubes to treat an elderly patient with primary central nervous system lymphoma (PCNSL). The patient was a 76-year-old woman who underwent endoscopic biopsy of multiple intracerebral masses, which resulted in the diagnosis of diffuse large B-cell lymphoma. The patient was diagnosed with PCNSL and was started on an induction regimen of systemic chemotherapy with rituximab in combination with high-dose methotrexate. However, after the second cycle of chemotherapy, the tumor grew rapidly, and the patient went into a coma. As a result, the treatment was changed to nasogastric tube administration of tirabrutinib suspension. After 1 week of tirabrutinib administration, the patient's level of consciousness improved, and furthermore, after 2 weeks of tirabrutinib administration, the patient was able to take tirabrutinib orally. Although oral administration is the standard route of administration for tirabrutinib, this case study showed that the nasogastric tube administration of tirabrutinib suspension is a therapeutic option for patients with impaired consciousness or dysphagia. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Elderly; Primary central nervous system lymphoma; Tirabrutinib

Year:  2021        PMID: 34567940      PMCID: PMC8421486          DOI: 10.1007/s13691-021-00491-1

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  15 in total

1.  Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Authors:  Christian Grommes; Alessandro Pastore; Nicolaos Palaskas; Sarah S Tang; Carl Campos; Derrek Schartz; Paolo Codega; Donna Nichol; Owen Clark; Wan-Ying Hsieh; Dan Rohle; Marc Rosenblum; Agnes Viale; Viviane S Tabar; Cameron W Brennan; Igor T Gavrilovic; Thomas J Kaley; Craig P Nolan; Antonio Omuro; Elena Pentsova; Alissa A Thomas; Elina Tsyvkin; Ariela Noy; M Lia Palomba; Paul Hamlin; Craig S Sauter; Craig H Moskowitz; Julia Wolfe; Ahmet Dogan; Minhee Won; Jon Glass; Scott Peak; Enrico C Lallana; Vaios Hatzoglou; Anne S Reiner; Philip H Gutin; Jason T Huse; Katherine S Panageas; Thomas G Graeber; Nikolaus Schultz; Lisa M DeAngelis; Ingo K Mellinghoff
Journal:  Cancer Discov       Date:  2017-06-15       Impact factor: 39.397

Review 2.  Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.

Authors:  M Deckert; A Engert; W Brück; A J M Ferreri; J Finke; G Illerhaus; W Klapper; A Korfel; R Küppers; M Maarouf; M Montesinos-Rongen; W Paulus; U Schlegel; H Lassmann; O D Wiestler; R Siebert; L M DeAngelis
Journal:  Leukemia       Date:  2011-08-05       Impact factor: 11.528

3.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Authors:  Nancy D Doolittle; Agnieszka Korfel; Meredith A Lubow; Elisabeth Schorb; Uwe Schlegel; Sabine Rogowski; Rongwei Fu; Edit Dósa; Gerald Illerhaus; Dale F Kraemer; Leslie L Muldoon; Pasquale Calabrese; Nancy Hedrick; Rose Marie Tyson; Kristoph Jahnke; Leeza M Maron; Robert W Butler; Edward A Neuwelt
Journal:  Neurology       Date:  2013-05-17       Impact factor: 9.910

Review 4.  Tirabrutinib: First Approval.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2020-06       Impact factor: 9.546

5.  The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Authors:  Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

6.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

7.  Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.

Authors:  Igor T Gavrilovic; Adília Hormigo; Joachim Yahalom; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Authors:  Caroline Houillier; Luc Taillandier; Sylvain Dureau; Thierry Lamy; Mouna Laadhari; Olivier Chinot; Cecile Moluçon-Chabrot; Pierre Soubeyran; Remy Gressin; Sylvain Choquet; Gandhi Damaj; Antoine Thyss; Julie Abraham; Vincent Delwail; Emmanuel Gyan; Laurence Sanhes; Jérôme Cornillon; Reda Garidi; Alain Delmer; Marie-Laure Tanguy; Ahmad Al Jijakli; Pierre Morel; Pascal Bourquard; Marie-Pierre Moles; Adrien Chauchet; Thomas Gastinne; Jean-Marc Constans; Adriana Langer; Antoine Martin; Patricia Moisson; Lucette Lacomblez; Nadine Martin-Duverneuil; Daniel Delgadillo; Isabelle Turbiez; Loïc Feuvret; Nathalie Cassoux; Valérie Touitou; Damien Ricard; Khê Hoang-Xuan; Carole Soussain
Journal:  J Clin Oncol       Date:  2019-02-20       Impact factor: 44.544

9.  Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.

Authors:  Yoshitaka Narita; Motoo Nagane; Kazuhiko Mishima; Yasuhito Terui; Yoshiki Arakawa; Hajime Yonezawa; Katsunori Asai; Noriko Fukuhara; Kazuhiko Sugiyama; Naoki Shinojima; Junsaku Kitagawa; Arata Aoi; Ryo Nishikawa
Journal:  Neuro Oncol       Date:  2021-01-30       Impact factor: 12.300

10.  Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.

Authors:  Ryohei Kozaki; Meike Vogler; Harriet S Walter; Sandrine Jayne; David Dinsdale; Reiner Siebert; Martin J S Dyer; Toshio Yoshizawa
Journal:  Cancers (Basel)       Date:  2018-04-23       Impact factor: 6.639

View more
  1 in total

1.  Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia.

Authors:  Noriharu Nakagawa; Ruiko Yamano; Sayaka Kajikawa; Yukio Kondo; Hirokazu Okumura
Journal:  Leuk Res Rep       Date:  2022-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.